Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.03 | N/A | -84.62% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.03 | N/A | -84.62% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current market conditions affecting performance. They remain focused on strategic initiatives for future growth.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term goals despite short-term setbacks.
The earnings report indicates that Krystal Biotech faced significant challenges this quarter, particularly reflected in the EPS miss. The stock's reaction, dropping 2.58%, suggests investor disappointment. Without revenue figures or updated guidance, uncertainty remains about the company's short-term outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HERSHEY CO
May 3, 2024